Table 3.

Hazard ratio (HR) of clinical and genomic variables on overall survival via univariate and multivariate analysis in patients treated with Docetaxel.

Variable	POPLAR cohort – Docetaxel (n=106)
	Uni-variate		Multi-variate
	HR (95% Cl)	P	HR (95% Cl)	P
SEX (male vs female)	1.53 (0.99-2.36)	0.0531
Age (>60 vs ≤60)	1.04 (0.68-1.59)	0.8591
Race (white vs non- white)	1.55 (0.85-2.8)	0.1497
Smoking (smoker vs non-smoker)	1.67 (0.92-3.02)	0.0903
HIST (non-squamous vs squamous)	1.19 (0.77-1.84)	0.4217
bTMB (>median vs <median)	1.92 (1.25-2.96)	0.0029	1.65 (1.03-2.64)	0.037
baseline SLD (>median vs <median)	1.4 (0.92-2.14)	0.1153
SRP status (mut vs wt)	2.17 (1.31-3.6)	0.0026	1.69 (0.98-2.93)	0.059
Variable	OAK cohort – Docetaxel (n=318)
	Uni-variate		Multi-variate
	HR (95% Cl)	P	HR (95% Cl)	P
SEX (male vs female)	1.15 (0.89-1.48)	0.2953
Age (>60 vs ≤60)	1.26 (0.97-1.64)	0.0845
Race (white vs non- white)	1.26 (0.96-1.66)	0.0979
Smoking (smoker vs non-smoker)	1.3 (0.9-1.88)	0.158
HIST (non-squamous vs squamous)	1.43 (1.09-1.86)	0.0095	1.29 (0.98-1.69)	0.069
bTMB (>median vs <median)	1.57 (1.22-2.01)	<0.001	1.31 (1-1.73)	0.054
baseline SLD (>median vs <median)	1.55 (1.21-2)	<0.001	1.39 (1.07-1.81)	0.013
SRP status (mut vs wt)	1.54 (1.13-2.1)	0.0066	1.27 (0.91-1.77)	0.166
Variable	POPLAR/OAK cohort – Docetaxel (n=424)
	Uni-variate		Multi-variate
	HR (95% Cl)	P	HR (95% Cl)	P
SEX	1.23 (0.99-1.54)	0.0634
Age (>60 vs ≤60)	1.21 (0.97-1.51)	0.0992
Race (white vs non-white)	1.32 (1.03-1.7)	0.0268	1.15 (0.13-1.08)	0.279
Smoking (smoker vs non-smoker)	1.41 (1.03-1.93)	0.0305	1.06 (0.18-0.34)	0.736
HIST (squamous vs non-squamous)	1.36 (1.08-1.71)	0.008	1.25 (0.12-1.83)	0.067
bTMB (>median vs <median)	1.64 (1.32-2.03)	<0.001	1.34 (0.12-2.36)	0.018
baseline SLD (>median vs <median)	1.5 (1.21-1.87)	0.0002	1.33 (0.11-2.52)	0.012
SRP status (mut vs wt)	1.66 (1.28-2.16)	0.0002	1.33 (0.15-1.99)	0.047